Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Eukaryotic translation termination factor 1 pseudogene 2 (ETF1P2) is a non-coding, processed pseudogene derived from the *ETF1* gene, which encodes a class-1 polypeptide chain release factor important for translation termination. Pseudogenes like ETF1P2 may be transcribed in some contexts but do not encode active proteins, lack canonical promoter and regulatory elements, and are generally considered non-functional genomic fossils. There are no established roles for ETF1P2 in human biology or disease, nor is it considered a drug target or therapeutic/receptor molecule[1][3]. Critical notes: - ETF1P2 should not be confused with *ETF1* (the protein-coding gene encoding eukaryotic translation termination factor 1), which does have known functions in translation termination and RNA surveillance processes[2]. - The inclusion of ETF1P2 as a target in therapeutic databases is incorrect due to its pseudogene status[1]. - No interacting drugs, mechanisms of action, or known biomarker or disease utility are associated with ETF1P2[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic translation termination factor 1 pseudogene 2 (ETF1P2).